Voronoi has confirmed the anti-cancer efficacy of its fourth-generation non-small cell lung cancer drug candidate VRN11 through early clinical trials. The company has demonstrated pharmacokinetics consistent with preclinical studies.
According to industry reports on Monday, the American Association for Cancer Research (AACR) recently released research abstracts related to Voronoi’s VRN11.
VRN11 is a fourth-generation drug candidate designed to treat patients who have developed resistance to third-generation lung cancer medications.
The published abstract reveals that Voronoi has confirmed dose-proportional pharmacokinetics (PK) results through a dose-escalation study in their Phase 1a clinical trial for VRN11, currently underway in South Korea and Taiwan. These findings align with predictions made during preclinical trials.
No dose-limiting toxicities or grade 1 or higher epidermal growth factor receptor (EGFR) related toxicities have been reported for VRN11 doses up to 80 mg.
Efficacy evaluations showed promising results. Patients with the C797S mutation after standard treatment received 40 mg of VRN11 and experienced a tumor reduction of over 40% after four weeks. For patients with the Del19 mutation, those treated with 80 mg saw a tumor decrease of more than 20% after three weeks.
Voronoi’s research team stated that the preclinical and early clinical results for VRN11 demonstrate its potential as a promising treatment option and that it could address the unmet medical needs of patients with progressive EGFR mutation non-small cell lung cancer, including those who have developed resistance to current standard treatments.